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In this presentation, three aspects of 
immunosuppressive treatment will be dealt 
with: first, recent experience with the use 
of cyclophosphamide in whole organ graft 
recipients; second, some interrelationships 
between the major immunosuppressive 
drugs and the liver; and finally, the im-
munosuppression used recently for hepatic 
transplant recipients. 
General Experience with Cyclophosphamide 
Cyclophosphamide has long been known 
to be an extremely effective immunosup-
pressant in rodents. In humans, the drug 
has been used extensively for cancer chemo-
therapy and for the treatment of auto-
immune disorders. Several years ago cyclo-
phosphamide was introduced by Santos 
and his associates into to the field of clini-
cal bone marrow grafting. There are prob-
ably tho reasons why cyclophosphamide 
has not been applied to clinical whole 
organ transplantation until recently. First, 
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a few trials in human kidney transplan-
tation almost a decade ago were complica-
ted by severe drug toxicity. Second, cyclo-
phosphamide was found not to prolong 
renal homograft survival in dogs. Although 
the latter findings were due to a species 
peculiarity, they were apparently extra-
polated to the human situation. 
For 16 months, cyclophosphamide has 
been used to replace azathioprine in a se-
ries of whole organ graft recipients in 
Denver [71. Prednisone and antilymphocyte 
globulin (ALG) has been administered as 
previously described. The daily dose of 
cyclophosphamide tolerated without undue 
toxicity has been 0.5-1 mg/kg or approxi-
mately half of that usually tolerated of 
azathioprine. Using such doses, bone mar-
row depression was observed about as 
frequently as with the old triple drug regi-
men containing azathioprine. Other side 
effects from cyclophosphamide were rare 
and consisted mainly of gastrointestinal 
symptoms. 
In renal homograft recipients, the results 
with cyclophosphamide have been very 
similar to those achieved previously with 
azathioprine. With a follow-up of 4 to 
16 months, the kidney survival among 39 
recipients of related grafts is 82 010 and the 
patient survival is 90 0/0. In a group of 36 
recipients of non-related cadaveric kidneys, 
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73 % have functioning grafts and 78 % of 
the patients are alive. Approximately half 
of the latter patients were retransplanted 
for the second to fifth time, and in these 
cases, the kidney survival was only 59 %. 
In contrast, the patients undergoing pri-
mary cadaveric renal transplantation have 
a kidney survival exceeding 80 %. 
Kidney recipients have been treated with 
cyclophosphamide rather than azathioprine 
for as long as Ph years. However, it is our 
present practice to use cyclophosphamide 
for approximately 2 months and then switch 
to azathioprine. This will be described in 
the last section of this article. 
Immunosuppression and the Liver 
Hepatotoxicity is obViously an undesirable 
feature of any drug to be used in liver 
transplant recipients. Furthermore, if the 
activation or the degradation of the drug 
occurs mainly in the liver, this will have 
special implications in such patients. 
Azathioprine may be hepatotoxic in hu-
mans. In controlled studies in animals, the 
usual signs of toxicity are rises in serum 
transaminases and the alkaline phosphatase 
[8], although in one study an increase in 
bilirubin was also noted [1]. In humans, 
azathioprine is by no means as hepatotoxic 
as in dogs. Yet, there have been a number 
of cases in which azathioprine may have 
played a role in causing liver injury after 
renal transplantation [9,10]. Administration 
of the main metabolite of azathioprine, 
6-mercaptopurine, has also been shown to 
cause liver damage, as for instance, when 
used in leukemic patients [4]. 
Although cyclophosphamide, given in 
very high doses, has been found to cause 
liver damage in rodents, patients have been 
treated with the drug for several years 
without evidence of significant liver tox-
icity [5]. In the Denver kidney transplant 
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recipients, the incidence of liver dysfunc-
tion was similar whether azathioprine or 
cyclophosphamide was used [7], but the 
numerous factors involved make an eva-
luation of the effect of the individual drugs 
difficult. 
Corticosteroids, including prednisone, 
may cause hepatomegaly and fatty degene-
ration of the liver in animals, but the 
incidence of this complication in humans 
under prolonged treatment is difficult to 
determine. There is no evidence that ALG 
has a significant hepatotoxic effect [2]. 
The reverse question concerning the ef-
fect of the liver on the metabolism of 
immunosuppressive drugs, might also be 
of consequence in hepatic transplant recip-
ients. The way in which this factor could 
influence the daily doses of azathioprine 
in both dogs and man has been speculated 
upon [6, 9]; the same considerations apply 
to cyclophosphamide. Cyclophosphamide 
becomes an active immunosuppressive 
agent first after an in vivo activation pro-
cess in which the liver plays an important 
role [3]. Consequently, the drug might be-
come less activated and thus decreasingly 
immunosuppressive if the liver function 
deteriorates. To date, there is no direct 
evidence from experience with hepatic 
transplantation that this occurs, but the 
possibility will have to be borne in mind 
in future cases. 
Alternatively, since the degradation and 
detoxification of azathioprine, cyclophos-
phamide, and prednisone occurs mainly in 
the liver, it could be suggested that the 
effe,::t of the drugs would become enhanced 
with liver dysfunction. In fact, some evi-
dence has been adduced that renal trans-
plant recipients require reduced immuno-
suppression, particularly of azathioprine, 
when afflicted with severe liver dysfunc-
tion. However, the practical implications of 
the described interactions between the im-
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I\unosuppressive drugs and the liver for 
tie care of the hepatic transplant recipient 
~main obscure. 
'resent Practices of Immunosuppression 
Immunosuppression in hepatic transplant 
f""cipients has been founded on experience 
~Ecumulated in large series of renal trans-
rlant patients. Before 1966, treatment was 
,ith azathioprine and prednisone and no 
long term survivals were obtained. 
In the first triple drug regimen intro-
duced in 1966, azathioprine was given con-
tinuously in the maximum dose tolerated 
Nithout leukopenia, the prednisone dose 
was adjusted according to the vigor of 
rejection, and ALG was given in a standard 
::lose for the first 2-4 postoperative months. 
[ntravenous Actinomycin C and local graft 
~radiation were occasionally used as sup-
plemental immunosuppressive measures 
iuring homograft rejection. 
In many cases, the course of ALG was 
prolonged to several months or even years. 
In addition, the practice was introduced 
of giving large doses of intravenous corti-
costeroids, first prednisone and later methyl-
prednisone, for rejection or sometimes pro-
phylactically. With this program, one year 
survival of 25 Ofo to 30 Ofo was achieved from 
1967 to 1970. 
In the last 16 months, azathioprine has 
been replaced with cyclophosphamide during 
the initial postoperative treatment. In the 
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first liver transplant patients on this regi-
men, the cyclophosphamide was continued 
for 9 months. More recently, the protocol 
has been adjusted in that cyclophosphamide 
is now given only for the first 1 to 2 months, 
following which a change is made to azathio-
prine. The rationale for such a successive 
use of two cytotoxic agents lies in their 
dissimilarity of structure and of action. 
Cyclophosphamide is an alkylating agent 
and azathioprine is a purine analogue. The 
two drugs are thought to act at different 
stages of the cell cycle and might thus have 
a reinforcing effect when given serially. 
The consecutive use of drugs in order to 
achieve "longitudinal synergism" in con-
trast to the synergism of simultaneously 
administered agents is common in cancer 
chemotherapy. With this new practice, we 
have limited ALG to the first few post-
operative months. 
A total of 15 recipients of orthotopic 
hepatic grafts have now been treated with 
a drug regimen including cyclophosphamide. 
Six of the patients are alive and well with 
a follow-up of 2-16 months. 
Summary 
Recent experience with the use of cyclo-
phosphamide in whole organ graft recipients 
is described. The interrelationship between 
the major immunosuppressive drugs and 
the liver is discussed. Recent practice for 
clinical immunosuppression is outlined. 
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